Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,061 shares of the biopharmaceutical company’s stock, valued at approximately $124,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in SGMO. Bank of New York Mellon Corp lifted its position in Sangamo Therapeutics by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 333,305 shares of the biopharmaceutical company’s stock valued at $1,732,000 after acquiring an additional 19,142 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in Sangamo Therapeutics in the 1st quarter valued at about $578,000. American International Group Inc. lifted its position in Sangamo Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock valued at $222,000 after acquiring an additional 2,818 shares in the last quarter. Teachers Advisors LLC lifted its position in Sangamo Therapeutics by 9.8% in the 1st quarter. Teachers Advisors LLC now owns 180,858 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 16,130 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Sangamo Therapeutics by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock valued at $16,056,000 after acquiring an additional 239,544 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 124.3% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: “Virtu KCG Holdings LLC Purchases New Stake in Sangamo Therapeutics, Inc. (SGMO)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/02/virtu-kcg-holdings-llc-purchases-new-stake-in-sangamo-therapeutics-inc-sgmo.html.
Several equities analysts recently weighed in on SGMO shares. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Piper Jaffray Companies set a $8.00 price target on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Thursday, August 10th. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $30.00 price target (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $14.40.
In other news, Director William R. Ringo sold 31,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total value of $445,470.00. Following the transaction, the director now owns 31,800 shares in the company, valued at $456,966. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Curt A. Herberts III sold 11,474 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $10.44, for a total transaction of $119,788.56. Following the completion of the transaction, the vice president now owns 23,991 shares in the company, valued at approximately $250,466.04. The disclosure for this sale can be found here. Insiders have sold 72,474 shares of company stock worth $1,019,009 in the last three months. 5.50% of the stock is currently owned by insiders.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).
What are top analysts saying about Sangamo Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sangamo Therapeutics Inc. and related companies.